Skip to content
PubMed This is a summary of 10 peer-reviewed journal articles Updated
Pediatric Rheumatology · LACC1-Associated Juvenile Arthritis

Treating LACC1-Associated Arthritis

At a Glance

LACC1-associated juvenile arthritis has no single standard treatment. Pediatric rheumatologists tailor therapy to the child’s symptoms, often using biologics to control inflammation and aim for inactive disease while monitoring infections, blood tests, vaccine safety, steroid risks, and joint damage.

Because LACC1-associated juvenile arthritis is extremely rare, there is currently no single, universally accepted treatment protocol [1]. Instead, pediatric rheumatologists follow the established principles for treating severe juvenile idiopathic arthritis (JIA) and systemic JIA (sJIA), while acknowledging that this genetic form is often “refractory,” meaning it can be very difficult to control with standard medications [2].

The primary goal of treatment is treat-to-target. This means your medical team is aiming for clinically inactive disease: no active joints, resolved systemic symptoms (like fevers), normal function, and laboratory results (like CRP and ESR) that are normal or acceptably low for the clinical context [3][2]. (Note that some treatments, such as tocilizumab, can artificially suppress CRP, so laboratory results alone cannot define control).

Treatment Options

Treatment is highly individualized. Medications may be used alone or in combination, and while the options below are common, they are examples rather than a rigid protocol:

  1. Conventional DMARDs: Methotrexate is frequently prescribed and is useful for some articular disease. However, studies of children with the LACC1 mutation show that methotrexate is often not universally the best treatment for systemic features, and many require additional therapy to stop disease progression [2].
  2. Biologic Therapy: Depending on the severity and phenotype, contemporary management often uses biologic agents early:
    • IL-1 Inhibitors (Anakinra, Canakinumab): These are often used when the disease looks like systemic JIA (with fevers and rashes). They block interleukin-1, a major inflammatory “messenger” [4][5].
    • IL-6 Inhibitors (Tocilizumab): These block interleukin-6 and have been used successfully in some children with LACC1 mutations to help control both joint and systemic symptoms [1][6].
  3. JAK Inhibitors: In cases where biologics fail, drugs called JAK inhibitors (such as tofacitinib) may be considered. However, evidence for LACC1 disease is anecdotal (based on a single reported response), and approval and age indications vary. JAK inhibitors require strict monitoring due to boxed warnings for serious infections, laboratory abnormalities, and thrombosis [6][7].

Managing Inflammation Quickly

During severe flares, doctors may use glucocorticoids (steroids like prednisone). While steroids are excellent at putting out the “fire” of inflammation quickly, they carry significant long-term risks, such as growth suppression, bone weakness, and infection risk [8][9].

Crucial Safety Rule: Steroids must never be stopped abruptly, as this can cause a life-threatening adrenal crisis or a rebound flare. Tapering depends on disease control and must be done exclusively under the treating team’s instructions.

Medication Safety Plan

Because these medications suppress the immune system, you must have a clear safety plan in place:

  • Infection Precautions: Know exactly who to call and when to go to the emergency department for a fever or suspected infection.
  • Lab Monitoring: Adhere to scheduled blood tests (like CBC and liver enzymes) to safely monitor drug toxicity.
  • Vaccinations: Discuss vaccine schedules with your rheumatologist. Live vaccines are generally contraindicated while on biologics or high-dose immunosuppressants [10].

The Challenge of Progressive Damage

It is important for parents to know that even with aggressive treatment, this specific genetic condition can be stubborn. In a historical cohort of 43 patients, 86% continued to have progressive erosive arthritis (permanent joint damage) [2]. This highlights the importance of early diagnosis and frequent clinical monitoring, though newer targeted therapies may help improve outcomes beyond what was seen in older studies.

Common questions in this guide

What treatments are used for LACC1-associated juvenile arthritis?
There is no single universally accepted treatment protocol because this condition is extremely rare. Pediatric rheumatologists individualize care using treatments for severe juvenile idiopathic arthritis or systemic juvenile arthritis, which may include methotrexate, biologic medicines, JAK inhibitors, and steroids for severe flares.
What does treat-to-target mean for LACC1-associated arthritis?
Treat-to-target means aiming for clinically inactive disease: no active joints, resolved fevers or other systemic symptoms, normal function, and laboratory results that are normal or acceptably low. Doctors interpret blood tests alongside the child’s clinical condition because tocilizumab can lower CRP even when it does not tell the whole story.
Are biologic medicines used early for LACC1-associated arthritis?
They may be considered early when the disease is severe or has systemic features. IL-1 medicines such as anakinra or canakinumab may help with fever and rash patterns, while the IL-6 medicine tocilizumab may help control joint and systemic symptoms.
Can my child stop steroids when symptoms improve?
Steroids must never be stopped abruptly, even if symptoms improve. The treating team must create and supervise a gradual taper because sudden withdrawal can cause a dangerous adrenal crisis or a rebound flare.
What safety monitoring does treatment require?
Families should know when to call the medical team or seek emergency care for fever or suspected infection. Scheduled blood tests, including blood counts and liver enzymes, help monitor medication safety, and vaccine decisions should be reviewed with the rheumatologist because live vaccines are generally avoided during biologic or high-dose immunosuppressive treatment.
Can LACC1-associated arthritis cause permanent joint damage?
It can be difficult to control, and a historical group of patients had progressive erosive arthritis despite treatment. Early specialist care and frequent monitoring are important, while newer targeted therapies may improve outcomes compared with older reports.

Get notified when new evidence is published on juvenile arthritis due to defect in LACC1.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (10)
  1. 1

    [Monogenic variants in Laccase domain-containing 1 (LACC1) as the cause of juvenile arthritis].

    Knieper AM, von Stuckrad ASL, Minden K, et al.

    Zeitschrift fur Rheumatologie 2024; (83(1)):4-14 doi:10.1007/s00393-023-01442-2.

    PMID: 37921883
  2. 2

    New or vanishing frontiers: LACC1-associated juvenile arthritis.

    Al-Mayouf SM, Yateem M, Al-Dusery H, et al.

    International journal of pediatrics & adolescent medicine 2021; (8(1)):44-47 doi:10.1016/j.ijpam.2020.11.005.

    PMID: 33718577
  3. 3

    Practice and consensus-based strategies in diagnosing and managing systemic juvenile idiopathic arthritis in Germany.

    Hinze CH, Holzinger D, Lainka E, et al.

    Pediatric rheumatology online journal 2018; (16(1)):7 doi:10.1186/s12969-018-0224-2.

    PMID: 29357887
  4. 4

    Pan American League of Associations for Rheumatology treatment recommendations for systemic juvenile idiopathic arthritis.

    Franco L, Rodrigues Fonseca A, Barzola ML, et al.

    Rheumatology advances in practice 2025; (9(4)):rkaf087 doi:10.1093/rap/rkaf087.

    PMID: 41234672
  5. 5

    Treatment to Target Using Recombinant Interleukin-1 Receptor Antagonist as First-Line Monotherapy in New-Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five-Year Follow-Up Study.

    Ter Haar NM, van Dijkhuizen EHP, Swart JF, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2019; (71(7)):1163-1173 doi:10.1002/art.40865.

    PMID: 30848528
  6. 6

    LACC1 deficiency leading to juvenile arthritis and anemia.

    He T, Wang L, Huang X, et al.

    Clinical immunology (Orlando, Fla.) 2024; (265()):110290 doi:10.1016/j.clim.2024.110290.

    PMID: 38944365
  7. 7

    Efficacy and safety of tofacitinib in the treatment of refractory cases of polyarticular course juvenile idiopathic arthritis: A study from Bangladesh.

    Rahman MM, Laila K, Rahman SA

    International journal of rheumatic diseases 2022; (25(6)):678-684 doi:10.1111/1756-185X.14324.

    PMID: 35435319
  8. 8

    Growth Failure in Children with Systemic Juvenile Idiopathic Arthritis and Prolonged Inflammation despite Treatment with Biologicals: Late Normalization of Height by Combined Hormonal Therapies.

    de Zegher F, Reynaert N, De Somer L, et al.

    Hormone research in paediatrics 2018; (90(5)):337-343 doi:10.1159/000489778.

    PMID: 29940586
  9. 9

    Prognosis, complications and treatment response in systemic juvenile idiopathic arthritis patients: A single-center experience.

    Barut K, Adrovic A, Sahin S, et al.

    International journal of rheumatic diseases 2019; (22(9)):1661-1669 doi:10.1111/1756-185X.13649.

    PMID: 31273940
  10. 10

    Juvenile Idiopathic Arthritis.

    Barut K, Adrovic A, Şahin S, Kasapçopur Ö

    Balkan medical journal 2017; (34(2)):90-101 doi:10.4274/balkanmedj.2017.0111.

    PMID: 28418334

This page explains treatment and medication safety for LACC1-associated juvenile arthritis for educational purposes. A pediatric rheumatologist should tailor treatment, monitoring, steroid tapering, and vaccine decisions to your child.